UNIVERSITY OF DUNDEE AND CORBIN THERAPEUTICS ENTER INTO COLLABORATION AGREEMENT TO DISCOVER NOVEL UBIQUITIN-SPECIFIC PROTEASE INHIBITORS

Dundee, Scotland UK and Montreal, Québec, Canada, May 22, 2017 – University of Dundee, its Drug Discovery Unit (“DDU”), and Corbin Therapeutics (“Corbin”) are pleased to announce their collaboration agreement to screen and identify small molecules capable of efficiently inhibiting a well-conserved ubiquitin-specific protease, USP15. Corbin focuses on a novel therapeutic approach to treat various[…]

CORBIN THERAPEUTICS AND PROTEOREX THERAPEUTICS ANNOUNCE A RESEARCH AND DEVELOPMENT COLLABORATION TO DISCOVER NOVEL UBIQUITIN-SPECIFIC PROTEASE INHIBITORS

Toronto, ON, and Montreal, QC, May 19, 2017 – Proteorex Therapeutics Inc. (“Proteorex”), headquartered in JLABS @ Toronto, is excited to announce the start of their research and development collaboration with Montreal-based Corbin Therapeutics Inc. (“Corbin”). The collaboration will identify small molecules which efficiently inhibit an important and highly conserved ubiquitin protein. Proteorex will receive[…]

AMORCHEM SPINS OUT ITS USP15-DEUBIQUITINYLATION (DUB) DRUG DISCOVERY PLATFORM INTO CORBIN THERAPEUTICS, WITH A FIRST 1M$ SEED INVESTMENT

Montreal, Quebec – January 9, 2017 – AmorChem is pleased to announce the creation of Corbin Therapeutics, its third spin-off company focusing on a novel therapeutic approach to treat various inflammation-based diseases via inhibition of the ubiquitin carboxyl-terminal hydrolase 15 (USP15) enzyme. All rights to the USP15 technology initially held by AmorChem have been transferred[…]